Inosine is widely available to consumers in dietary supplement form. The researchers emphasize that people with Parkinson's should not take inosine except in the context of a closely monitored clinical trial in which potential benefits and risks are carefully balanced. The evidence to date surrounding inosine and PD does not prove a cause-effect relationship. Additionally, elevated urate levels are known to carry certain health risks, only some of which have been definitively characterized to date. Kidney stones and gout are known risks; cardiovascular disease is a possible risk. (In the clinical trial, safety measures will be in place to help avoid these conditions, and to detect and treat them should they arise.)
LEAPS awards are multi-year, multi-million-dollar awards to teams of key experts who focus on answering major questions that can improve the diagnosis and treatment of Parkinson's disease. This third and final 2007 LEAPS award is the Foundation's single largest award to date. It brings the total funding under the 2007 LEAPS program to $13.8 million.
The principal investigators of this LEAPS award are:
-- Coordinating principal investigator Michael A. Schwarzschild, MD, PhD, of the MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital, will oversee all elements of the trial.
-- Co-principal investigator Alberto Ascherio, MD, DrPH, of the Harvard School of Public Health, will assist in all aspects of trial design and data analysis and head the main biostatistician team.
-- Co-principal investigator Karl Kieburtz, MD, MPH, of the University
of Rochester School of Medicine and Denti
|SOURCE Michael J. Fox Foundation|
Copyright©2008 PR Newswire.
All rights reserved